Masoud, M., Soliman, R., Senousy, A., Kamel, N., Elmonem, N. (2024). Role of Neurofilament Light Chain in Relapsing Remitting Multiple Sclerosis Patients. test, 1(1), 1-14. doi: 10.21608/ijabmb.2024.359914
Mohammed Mabrouk Masoud; Rasha Hasan Soliman; Ahmed Nabil Senousy; Nesreen Mostafa Kamel; Noha Ali Abd Elmonem. "Role of Neurofilament Light Chain in Relapsing Remitting Multiple Sclerosis Patients". test, 1, 1, 2024, 1-14. doi: 10.21608/ijabmb.2024.359914
Masoud, M., Soliman, R., Senousy, A., Kamel, N., Elmonem, N. (2024). 'Role of Neurofilament Light Chain in Relapsing Remitting Multiple Sclerosis Patients', test, 1(1), pp. 1-14. doi: 10.21608/ijabmb.2024.359914
Masoud, M., Soliman, R., Senousy, A., Kamel, N., Elmonem, N. Role of Neurofilament Light Chain in Relapsing Remitting Multiple Sclerosis Patients. test, 2024; 1(1): 1-14. doi: 10.21608/ijabmb.2024.359914

Role of Neurofilament Light Chain in Relapsing Remitting Multiple Sclerosis Patients

International Journal of Applied Biochemistry and Molecular Biology
Volume 1, Issue 1, January 2024, Pages 1-14    PDF (284.09 K)
Document Type: Original Article
DOI: 10.21608/ijabmb.2024.359914
Authors
Mohammed Mabrouk Masoud1; Rasha Hasan Soliman1; Ahmed Nabil Senousy* 2; Nesreen Mostafa Kamel3; Noha Ali Abd Elmonem1
1Neurology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
2Neurology Department, Elsahel Teaching Hospital, Cairo, Egypt
3Clinical and Chemical Pathology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Abstract
 Background: Neurofilament light chain (NfL) is released from damaged neurons and elevated levels in the blood reflect ongoing neuroaxonal injury in multiple sclerosis (MS). Assessing NfL levels could provide insight into disease activity and treatment responses in MS patients.
Objective: To investigate the relationship of plasma NfL levels with clinical and MRI parameters and disability scores in relapsing-remitting MS (RRMS) patients.
Patient and method: Plasma NfL concentrations were measured by ELISA in 42 RRMS patients in remission and 42 healthy matched controls. Associations with demographics, disease characteristics, MRI lesion counts, and Expanded Disability Status Scale (EDSS) scores were analyzed.
Results: RRMS patients had significantly higher NfL levels than controls (p=0.009). Levels were lower in treated vs untreated patients (p<0.001) and correlated positively with age, disease duration, relapse numbers, T2-lesion burden, and EDSS scores (p<0.05). No correlation was observed with the recent relapse rate or treatment duration.
Conclusion: Increased plasma NfL levels were associated with greater disability in RRMS patients and were lowered by treatment, indicating potential neuroprotective effects. NfL could be a useful biomarker in monitoring subclinical disease activity and treatment responses longitudinally. 
Statistics
Article View: 112
PDF Download: 99